Kiniksa Pharmaceuticals Ltd. (KNSA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Kiniksa Pharmaceuticals Ltd. (KNSA)
Go deeper and ask any question about KNSA
Company Performance
Current Price
as of Sep 13, 2024$25.26
P/E Ratio
N/A
Market Cap
$1.8B
Description
Kiniksa Pharmaceuticals International Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.
Metrics
Overview
- HQLexington, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerKNSA
- Price$25.26+3.14%
Trading Information
- Market Cap$1.80B
- Float54.37%
- Average Daily Volume (1m)280,328
- Average Daily Volume (3m)476,258
- EPS-$0.14
Company
- Revenue$338.93M
- Rev Growth (1yr)51.99%
- Net Income-$3.91M
- Gross Margin60.92%
- EBITDA Margin0.29%
- EBITDA$0.31M
- EV$1.12B
- EV/Revenue3.30
- P/EN/A
- P/S5.29